Impact of Craniocaudal Tumor Dimension and the Ninth Edition of the TNM Stage Classification on Prognosis in Resected Thymoma
Thoracic Cancer · 2025
DOI: 10.1111/1759-7714.70204 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Dai Okazaki und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan. Hauptthemen laut MEDLINE: Thymoma, Thymus Neoplasms. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Nagoya City University.
Abstract (Originalsprache)
Background
Thymoma is a rare thymic epithelial tumor, and its prognostic factors remain not fully elucidated. This study aimed to identify simple, practical preoperative predictors of prognosis, focusing on tumor dimensions assessed by computed tomography (CT).
Methods
We retrospectively analyzed 181 patients who underwent complete or partial resection for thymoma between 2004 and 2022. Tumor size was assessed by measuring the maximum transverse and craniocaudal dimensions on preoperative CT. Freedom from recurrence (FFR) and overall survival (OS) were estimated using the Kaplan–Meier method. Cox proportional hazards models were constructed: Model A included only preoperative variables, while Model B additionally incorporated postoperative factors (e.g., TNM stage classification and histology).
Results
During a median follow‐up of 96 months, the 5‐ and 10‐year FFR rates were 78.4% and 71.4%, and the corresponding OS rates were 96.5% and 87.3%, respectively. In multivariate analysis, TNM stage classification and preoperative steroid pulse therapy were significantly associated with FFR, whereas no variables were significantly associated with OS. Model A demonstrated good discriminatory ability ( C ‐index = 0.839), which improved only modestly after including postoperative factors in Model B ( C ‐index = 0.867). In the steroid‐excluded cohort ( N = 148), the craniocaudal tumor dimension emerged as a significant predictor of FFR ( p = 0.027).
Conclusions
The craniocaudal tumor dimension measured on preoperative CT was consistently associated with recurrence and may reflect prognostic information embedded within the pathological TNM classification. This easily measurable parameter could complement TNM‐based evaluation in preoperative risk assessment and surgical decision‐making for thymoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
- Department of Thoracic and Pediatric Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
- Department of Biostatistics and Health Data Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
ORCID-Profile: Dai Okazaki, Taiki Takaoka
Förderung
- Nagoya City University
Zitieren
APA
Okazaki, D., Tomita, N., Okuda, K., Nakatani, E., Aoki, G., Takaoka, T., Niwa, M., Torii, A., Kita, N., Takano, S., Oguri, M., & Hiwatashi, A. (2025). Impact of Craniocaudal Tumor Dimension and the Ninth Edition of the TNM Stage Classification on Prognosis in Resected Thymoma. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70204
Vancouver
Okazaki D, Tomita N, Okuda K, Nakatani E, Aoki G, Takaoka T, et al. Impact of Craniocaudal Tumor Dimension and the Ninth Edition of the TNM Stage Classification on Prognosis in Resected Thymoma. Thoracic Cancer. 2025. doi:10.1111/1759-7714.70204
BibTeX
@article{Okazaki2025,
author = {Okazaki, Dai and Tomita, Natsuo and Okuda, Katsuhiro and Nakatani, Eiji and Aoki, Gaku and Takaoka, Taiki and Niwa, Masanari and Torii, Akira and Kita, Nozomi and Takano, Seiya and Oguri, Masanosuke and Hiwatashi, Akio},
title = {Impact of Craniocaudal Tumor Dimension and the Ninth Edition of the TNM Stage Classification on Prognosis in Resected Thymoma},
journal = {Thoracic Cancer},
year = {2025},
doi = {10.1111/1759-7714.70204}
}
EUVIMED